This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Tissue-Specific Effects on Uptake of 99mTc-Sestamibi by Breast Lesions: A Targeted Analysis of False Scintigraphic Diagnoses
- Biodistribution, Radiation Dose Estimates, and In Vivo Pgp Modulation Studies of 18F-Paclitaxel in Nonhuman Primates
- Increased 99mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor, XR9576
- What Can We Expect from MDR Breast Cancer Imaging with Sestamibi?
- Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel
- Lack of Correlation of Functional Scintigraphy with 99mTechnetium-Methoxyisobutylisonitrile with Histological Necrosis following Induction Chemotherapy or Measures of P-Glycoprotein Expression in High-Grade Osteosarcoma
- Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin
- P-Glycoprotein and Multidrug Resistance-related Protein Expressions in Relation to Technetium-99m Methoxyisobutylisonitrile Scintimammography Findings
- A New in Vivo Method to Study P-Glycoprotein Transport in Tumors and the Blood-Brain Barrier